| __timestamp | Regeneron Pharmaceuticals, Inc. | Taro Pharmaceutical Industries Ltd. |
|---|---|---|
| Wednesday, January 1, 2014 | 504755000 | 91733000 |
| Thursday, January 1, 2015 | 838526000 | 87644000 |
| Friday, January 1, 2016 | 1177697000 | 92365000 |
| Sunday, January 1, 2017 | 1320433000 | 85656000 |
| Monday, January 1, 2018 | 1556200000 | 88196000 |
| Tuesday, January 1, 2019 | 1834800000 | 89971000 |
| Wednesday, January 1, 2020 | 1346000000 | 93413000 |
| Friday, January 1, 2021 | 1824900000 | 91355000 |
| Saturday, January 1, 2022 | 2115900000 | 113676000 |
| Sunday, January 1, 2023 | 2631300000 | 198366000 |
| Monday, January 1, 2024 | 2954400000 | 218935000 |
Cracking the code
In the competitive world of pharmaceuticals, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, Regeneron Pharmaceuticals, Inc. and Taro Pharmaceutical Industries Ltd. have shown contrasting trends in their SG&A expenses. From 2014 to 2023, Regeneron saw a staggering 420% increase in SG&A expenses, peaking in 2023. This growth reflects their aggressive expansion and investment in marketing and administration. In contrast, Taro's SG&A expenses remained relatively stable, with a modest 116% increase over the same period, indicating a more conservative approach. Notably, Regeneron's expenses surged significantly in 2022 and 2023, while Taro's expenses showed a steady rise, with a notable jump in 2023. These trends highlight the strategic differences between the two companies in navigating the pharmaceutical landscape.
Eli Lilly and Company vs Regeneron Pharmaceuticals, Inc.: SG&A Expense Trends
Eli Lilly and Company vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Novo Nordisk A/S or Taro Pharmaceutical Industries Ltd.: Who Manages SG&A Costs Better?
Who Optimizes SG&A Costs Better? Novartis AG or Taro Pharmaceutical Industries Ltd.
Who Optimizes SG&A Costs Better? Regeneron Pharmaceuticals, Inc. or Protagonist Therapeutics, Inc.
Comparing SG&A Expenses: Regeneron Pharmaceuticals, Inc. vs Mesoblast Limited Trends and Insights
Regeneron Pharmaceuticals, Inc. and Dynavax Technologies Corporation: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? Genmab A/S or Taro Pharmaceutical Industries Ltd.
Summit Therapeutics Inc. vs Taro Pharmaceutical Industries Ltd.: SG&A Expense Trends
Cost Management Insights: SG&A Expenses for Verona Pharma plc and Taro Pharmaceutical Industries Ltd.
Breaking Down SG&A Expenses: Agios Pharmaceuticals, Inc. vs Taro Pharmaceutical Industries Ltd.
Selling, General, and Administrative Costs: Taro Pharmaceutical Industries Ltd. vs Xencor, Inc.